| Type | Title | Date Released | |
|---|---|---|---|
6-K | Scinai Reports First Nine Months 2026 Financial Results and CDMO Business Expansion New | ||
F-3 | SHARE RESALE REGISTRATION | ||
6-K | Completed financing and CDMO agreement boost committed orders to $8.1 million, extending operating runway potentially into third-quarter 2028 | ||
6-K | Scinai Immunotherapeutics Closes $4.0 Million Financing Through Private Placement and Warrant Inducement | ||
6-K | Scinai Immunotherapeutics Announces $4.0 Million Financing Through a Private Placement and Warrant Inducement | ||
6-K | Scinai Expands CDMO Business with $5.1 Million Development and Clinical Manufacturing Agreement | ||
EFFECT | Form EFFECT | ||
F-1 | YA II PN, Ltd. - SPA - 97% of the lowest daily VWAP over 3 trading days starting on the notice date (also described as starting the next trading day). No fixed floor; the company can set a minimum. Daily maximum and ownership cap percentage are not stated in the excerpts. EFFECTIVE, DATED 2026-10-05 | ||
6-K | Scinai Regains Compliance with Nasdaq Minimum Bid Price Requirement | ||
6-K | Scinai Concludes PC111 Arrangements and Refocuses Capital on NanoAb Platform and Growing CDMO Business | ||
EFFECT | Form EFFECT | ||
POS AM | SPA | Shares: 439,942 EFFECTIVE, DATED 2026-08-28 |
